Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study - Concepedia

Concepedia

Publication | Open Access

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

DOI Full Paper Access

33

Citations

21

References

2022

Year

Daniel J Stieh, Dan H. Barouch, Christy Comeaux, Michal Sarnecki, Kathryn E. Stephenson, Stephen R. Walsh, Sheetal Sawant, Jack Heptinstall, Georgia D. Tomaras, James G. Kublin,

The Journal of Infectious Diseases

Abstract

Adding mosaic gp140 to the clade C regimen increased and broadened the elicited immune response without compromising safety or clade C responses. Clinical Trials Registration. NCT02935686.

References

	Year	Citations

Page 1